Ortho-McNeil, J&J to Use Cellzome Proteomics Tech in Alzheimer’s Research Program

Cellzome last week said that it will collaborate with Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Pharmaceutical, in a drug-discovery research program for Alzheimer’s disease.

Cellzome will apply its chemical proteomics technology to the program, and will receive a technology-access fee and research funding for two years. The company said it is also eligible for development milestone payments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.